key: cord-0844010-fy0iiq11
authors: Doke, Purwa; Gothankar, Jayshree Sachin; Doke, Prakash Prabhakarrao; Kulkarni, Milind Madhukar; Khalate, Kiran Kishanrao; Shrivastava, Shubham; Patil, Jayesh Rangrao; Arankalle, Vidya Avinash
title: Time dependent decline of neutralizing antibody titers in COVID-19 patients from Pune, India and evidence of reinfection
date: 2022-04-20
journal: Microbes Infect
DOI: 10.1016/j.micinf.2022.104979
sha: 258003fd43f9367c475cd6894f1fd558e34ee94c
doc_id: 844010
cord_uid: fy0iiq11

PURPOSE: To assess modulation of neutralizing antibody titers in COVID-19 patients and understand association of variables such as age, presence of comorbidity, BMI and gender with antibody titers. METHODS: Patients (n=100) diagnosed from 20(th) March 2020-17(th) August 2020 and treated at two large hospitals from Pune, India were included and followed up (clinical and serologic) for varied periods. IgG-anti-SARS-CoV-2 (Spike protein-based ELISA) and neutralizing antibody titers (NAb, PRNT) were determined in all the samples. RESULTS: Of the 100 patients enrolled initially (median 60 days of diagnosis), follow up samples were collected from 70 patients (median 106 days of diagnosis). Overall, NAb titers reduced significantly (p < 0.001) and as early as 3-4 months. During two visits, 20% and 7.1% patients reported some symptoms. At the first visit, NAb titers were higher in patients with severe disease (p<0.001), comorbidities (p<0.005), age <50 years (p<0.05) and male gender (p<0.05). Multivariate analysis identified older age (p<0.001), duration post-diagnosis and female gender as independent variables influencing NAb titers (negative correlation, p<0.05). During the follow-up, reduction in NAb titers was recorded in patients with comorbidity (p<0.05), mild disease (p<0.05), age <50years (p<0.05), higher BMI (p<0.05) and male gender (p <0.001). Serology identified six cases of asymptomatic reinfections. CONCLUSIONS: Decline of NAb titers was associated with age<50 years, mild disease, comorbidities, higher BMI and male gender. At the time of follow up, 8/70 (11.4%) patients lacked neutralizing antibodies. Evidence of 6 probable asymptomatic reinfections suggests waning of immunity, but, probable protection from clinical disease needing hospitalization.

The unprecedented pandemic of COVID-19 disease caused by SARS-CoV-2 continues to affect 51 global population and economies. So far, the virus has infected 222 countries leading to 212.6 52 million patients and 4.4 million deaths (https://www.worldometers.info/coronavirus/#countries). 53 To combat the rapid spread of the infection, several vaccines were rapidly developed and made 54 available for immunization of different populations. To assess / predict efficacy of vaccines, it is 55 of utmost importance to understand immunologic basis for recovery from the disease as well as 56 progression to severity. Currently, correlates of protection for COVID-19 are not known. With the 57 emergence of several variants of concern globally, antibody response in general and neutralizing 58 antibody response in particular has gained additional significance. 59 In view of the decline in antibody titers in other corona viruses [1, 2] 

Characteristics of the study population 109 We recruited 100 COVID-19 patients; 81 with mild disease (mean age, 37.8+12.4 years, 46 males 110 and 35 females), 15 with moderate (mean age, 50.6+12.3 years, 11 males and 4 females) and 4 111 with severe disease (mean age, 53.3+12.2 years, 2 males and 2 females). Overall, fifty-nine males 112 and 41 females were recruited in this study. Twenty-six patients reported at least one co-morbidity 113 (Table1). Proportion of comorbidities was higher in non-mild than mild infections (p<0.001). 114 Except one, all were non-smokers; According to Body Mass Index (BMI), 15 were obese while 29 115 J o u r n a l P r e -p r o o f 6 were overweight (44% with higher BMI). A follow up sample could be collected from 70 patients 116 (59 with mild, 9 with moderate and 2 with severe disease). Of these, 38 were males and 32 were 117 females. Mean age for patients studied at both visits were comparable. The median duration 118 between sample collection and diagnosis of COVID-19 was 60 days (first visit) and 106 days 119 (second visit). with moderate and severe disease were grouped as non-mild cases for comparing disease severity. 143 At the first visit, higher titers were associated with the presence of comorbidities (p<0.005, figure   144 1A), non-mild disease (p<0.001, figure1B), age < 50years (p<0.05, figure 1C ) and male gender 145 (p<0.05, figure1D). Increased duration between COVID-19 diagnosis and sampling was 146 associated with a significant decline in NAb titers (p <0.005, figure 1F ). Multivariate analysis 147 identified age > 50 years (p<0.001), duration between diagnosis and sample collection and female 148 gender (negatively) as independent variables influencing NAb titers (p<0.05 for all). 149 At the second visit, significant differences were maintained only in relation to disease severity (Figure 2 ). For 42/70 (60%) patients, the initial sample was collected 30-59 days 163 after diagnosis. For the remaining patients, initial samples were collected at 2-3months (n=9, figure   164 2B), 3-4months (n=12, figure 2C ) and 4-5months (n=5, figure 2D ). In addition, 2 patients were 165 sampled for the first time at 5 and 6 months respectively. The first patient was negative for 166 neutralizing antibodies in the initial sample and at 6months follow up. The second patient exhibited 167 a titer of 348 at 6 months that increased to 2560 at 8 months. 168 Of the 39 patients tested within 1-2 months of diagnosis, a significant decline in NAb titers at 2-3 169 months (n=19, p<0.001) and at 3-4 months (n=20, p<0.001) was recorded (figure 2A). Of note, in Evidence of reinfection 178 We identified six possible asymptomatic reinfections during this study (Table 2) It is interesting to note that at the time of follow up visit, the difference in NAb titers was 212 maintained only in relation to the older age and severity, severity being higher in the patients > 50 213 years age. It therefore appears that the rates of antibody decline differ in patient groups categorized 214 on the basis of different parameters. In our study, the decline in antibody titers was associated with 215 comorbidity (p<0.05), age > 50years (p<0.05), higher BMI (p<0.05), male gender (p<0.001) and 216 mild disease (p<0.005). Thus, except for the patients with severe disease continuing to circulate 217 high NAb titers, these categories with high NAb titers in the initial samples did show a significant 218 decline. At the follow up visit, NAb titers were independent of comorbidity, BMI and gender. In-219 depth studies are required to understand the basis of differential declines in NAb titers in patient 220 categories with initial high titers. 221 Of concern, patients with mild disease did exhibit significant reduction in NAb titers. Further, NAb 222 negativity was found only in the mild patients at around 10% (9% at first visit and 11.4% at second Comparisons of NAb titers among 70 patients from whom a repeat sample was collected at 230 different time intervals led to some useful information (Figure 2 ). For 60% of these patients, the 231 initial sample was collected 1-2months post-diagnosis. A decline in NAb titers was evident for The finding of seroconversion at 6.5 months is noteworthy, the previous sample collected on 257 day116 being negative in PRNT and ELISA. Of concern, for two patients with >100 titer (107 and J o u r n a l P r e -p r o o f 

Longitudinal profile of antibodies against 270

SARS-coronavirus in SARS patients and their clinical significance

Longitudinal 311 observation and decline of neutralizing antibody responses in the three months following 312 SARS-CoV-2 infection in humans

Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody 316

Clinical, laboratory, and temporal predictors of neutralizing antibodies against SARS-CoV-2 among COVID-19 convalescent plasma donor candidates

CoV-2 IgG and Neutralizing Antibodies are Elevated in 323 Individuals with Poor Metabolic Health

The 326 association between obesity and peak antibody titer response in COVID-19 infection

Antibody Responses 8 329 Months after Asymptomatic or Mild SARS-CoV-2 Infection

Emergence 332 of two distinct variants of SARS-CoV-2 and an explosive second wave of COVID-19: the 333 experience of a tertiary care hospital in Pune

Infection-336 and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 337 variant

Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural 340

SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an 341 immunological study